Media Summary: Harry Erba, MD, PhD, professor of medicine, director, University of Alabama (UAB) Hematologic Malignancy Program, UAB ... Mattia D'Agostino, MD, University of Turin, European Myeloma Network, Turin, Italy, comments on how measurable residual ... In this video, Bruno Paiva, PhD, University of Navarra, Pamplona, Spain, shares some insights into the pros and cons of
Using Mrd To Guide Therapy - Detailed Analysis & Overview
Harry Erba, MD, PhD, professor of medicine, director, University of Alabama (UAB) Hematologic Malignancy Program, UAB ... Mattia D'Agostino, MD, University of Turin, European Myeloma Network, Turin, Italy, comments on how measurable residual ... In this video, Bruno Paiva, PhD, University of Navarra, Pamplona, Spain, shares some insights into the pros and cons of In this video, Caner Saygin, MD, University of Chicago, Chicago, IL, comments on Luciano Costa, MD, PhD, UAB School of Medicine, Birmingham, AL, comments on the Meletios Dimopoulos, MD, Kapodistrian University of Athens School of Medicine, Athens, Greece, comments on the potential for ...
Richard Stone, MD, Dana-Farber Cancer Institute, Boston, MA, comments on the Karthik Ramasamy, MBBS, MRCP, FRCPath, PhD, Oxford University Hospitals NHS Foundation Trust, Oxford, UK, discusses the ... Benjamin Derman, MD, The University of Chicago, Chicago, IL, discusses measurable residual disease ( Ola Landgren, MD, PhD, Sylvester Comprehensive Cancer Center, University of Miami, Miami, FL, discusses the importance of ... Benjamin Derman, MD, University of Chicago, Chicago, IL, shares insights into the Radhika Bansal, MBBS, Mayo Clinic, Rochester, MN, talks on the
Carsten Niemann, MD, PhD, from the Rigshospitalet, Copenhagen, Denmark, introduces the Phase II PHILEMON trial ... Neil Berinstein, MD, Sunnybrook Odette Cancer Centre, Toronto, Canada, discusses the debate between fixed-duration and ... Dr. Ben Derman of the University of Chicago presents a report on the prospective MRD2STOP study investigating sustained ... Ola Landgren, MD, PhD, from the Memorial Sloan Kettering Cancer Center, New York, NY, discusses how minimal residual ... Discover how measurable residual disease (
